The Medical Letter on Drugs and Therapeutics
Nebivolol (Bystolic) for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Nebivolol (Bystolic – Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.

PHARMACOLOGY — Like carvedilol and labetalol, nebivolol has vasodilating as well as beta-blocking effects, but unlike the other two drugs, which have alpha-blocking properties, nebivolol has nitric oxidemediated vasodilatory effects.1 At doses of up to 10 mg, nebivolol selectively antagonizes beta1-adrenergic receptors, causing a decrease in heart rate, myocardial contractility and renin activity. At higher doses, it antagonizes beta2 receptors and could cause bronchospasm and other symptoms as well. It has no intrinsic sympathomimetic activity. Nebivolol is highly lipophilic. Unlike some other beta-blockers, it apparently does not increase insulin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nebivolol (Bystolic) for Hypertension
Article code: 1281a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian